Gray matter changes in late life depression--a structural MRI analysis
- PMID: 18075490
- PMCID: PMC2872084
- DOI: 10.1038/sj.npp.1301655
Gray matter changes in late life depression--a structural MRI analysis
Abstract
Multiple brain morphometric changes have been reported in late-life depression (LLD), mostly in studies comparing volumes of circumscribed brain areas. The aim of our study is to characterize the volumetric changes of multiple gray matter regions in relation to age of onset/duration of illness. We predicted that the association of gray matter volumes with total duration of illness and age of onset would differ depending on whether the region was susceptible to the toxic effects of chronic exposure to cortisol or to the vascular/neurodegenerative changes accompanying prodromal dementia. Seventy-one elderly depressed subjects were studied along with thirty-two comparison subjects. High-resolution T1-weighted brain MRIs were processed using an automated labeling pathway technique. To protect against type-I error, we combined the right and left hemisphere volume data. We sampled 24 regions of interest (ROIs). We used the primary visual cortex volume to normalize for individual variations in brain size. LLD Subjects had smaller volumes than non-depressed subjects in 17 of the 24 examined ROIs. Shorter duration of illness and later age of onset was correlated with smaller volumes of parahippocampal area and parietal inferior area. A later age of onset was also correlated with smaller volumes of several frontal and temporal areas, cingulum, and putamen. Our findings support a dementia prodrome model more strongly than a toxic stress model in this group of subjects. However, it remains likely that both processes as well as other factors contribute to the heterogeneity of volumetric brain changes in LLD.
Conflict of interest statement
Carmen Andreescu, Meryl A Butters, Amy E Begley, Tarek Rajji, Minjie Wu, Howard Aizenstein, and Carolyn C Meltzer do not have any potential conflict to acknowledge. Charles F Reynolds III has received research support from GlaxoSmithKline, Pfizer Inc., Eli Lilly and Co., Bristol Meyers Squibb, and Forest Pharmaceuticals.
References
-
- Alexopoulos GS, Meyers BS, Young RC, Mattis S, Kakuma T. The course of geriatric depression with ‘reversible dementia’: a controlled study. Am J Psychiatry. 1993;150:1693–1699. - PubMed
-
- Almeida OP, Burton EJ, Ferrier N, McKeith IG, O’Brien JT. Depression with late onset is associated with right frontal lobe atrophy. Psychol Med. 2003;33:675–681. - PubMed
-
- Ballmaier M, Kumar A, Thompson PM, Narr KL, Lavretsky H, Estanol L, et al. Localizing gray matter deficits in late-onset depression using computational cortical pattern matching methods. Am J Psychiatry. 2004;161:2091–2099. - PubMed
-
- Bell-McGinty S, Butters MA, Meltzer CC, Greer PJ, Reynolds CF, III, Becker JT. Brain morphometric abnormalities in geriatric depression: long-term neurobiological effects of illness duration. Am J Psychiatry. 2002;159:1424–1427. - PubMed
-
- Bremner J. Changes in brain volume in major depression. Depression: Mind and Body. 2005;2:38–46.
Publication types
MeSH terms
Grants and funding
- R37 MH043832/MH/NIMH NIH HHS/United States
- R01 MH059945/MH/NIMH NIH HHS/United States
- K07 MH001410/MH/NIMH NIH HHS/United States
- K24 MH064625/MH/NIMH NIH HHS/United States
- MH64625/MH/NIMH NIH HHS/United States
- P30 MH071944/MH/NIMH NIH HHS/United States
- MH076079/MH/NIMH NIH HHS/United States
- R01 MH072947/MH/NIMH NIH HHS/United States
- R01 MH037869/MH/NIMH NIH HHS/United States
- MH43832/MH/NIMH NIH HHS/United States
- MH64678/MH/NIMH NIH HHS/United States
- MH59945/MH/NIMH NIH HHS/United States
- K23 MH064678/MH/NIMH NIH HHS/United States
- MH37869/MH/NIMH NIH HHS/United States
- R01 MH080240/MH/NIMH NIH HHS/United States
- MH071944/MH/NIMH NIH HHS/United States
- MH072947/MH/NIMH NIH HHS/United States
- R01 MH043832/MH/NIMH NIH HHS/United States
- R01 MH076079/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
